Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines

Vaccine

Volumn 29, Issue 11, 2011, Pages 2037-2043

  Liu, Heng ^a   Bungener, Laura ^a   ter Veer, Wouter ^a   Coller, Beth Ann ^b   Wilschut, Jan ^a   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HAWAII BIOTECH INC   (United States)

Author keywords

Adjuvant; Dose sparing; GPI 0100; Influenza; Vaccine

Indexed keywords

ADJUVANT; GPI 0100; H1N1 INFLUENZA SUBUNIT VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; SAPONIN DERIVATIVE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMORAL IMMUNITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SAPONINS; VACCINES, SUBUNIT;

EID: 79951812874     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.012     Document Type: Article

References (46)

1. Skeik N., Jabr F.I. Influenza viruses and the evolution of avian influenza virus H5N1. Int J Infect Dis 2008, 12:233-238.
2. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
3. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
4. Lye D.C., Ang B.S., Leo Y.S. Review of human infections with avian influenza H5N1 and proposed local clinical management guideline. Ann Acad Med Singapore 2007, 36:285-292.
5. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194:S111-S118.
6. Wilschut J.C., McElhaney J.E., Palache A.M. Vaccination: cornerstone of influenza control 2006, Elsevier, Amsterdam. 2nd ed.
7. Palese P. Making better influenza virus vaccines?. Emerg Infect Dis 2006, 12:61-65.
8. Baras B., Bouveret N., Devaster J.M., Fries L., Gillard P., Sanger R., et al. A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi Viruses 2008, 2:251-260.
9. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1796.
10. Barr I.G., Sjölander A., Cox J.C. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998, 32:247-272.
11. Marciani D.J., Reynolds R.C., Pathak A.K., Finley-Woodman K., May R.D. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 2003, 21:3961-3972.
12. Marciani D.J., Press J.B., Reynolds R.C., Pathak A.K., Pathak V., Gundy L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 2000, 18:3141-3152.
13. Ragupathi G., Yeung K.S., Leung P.C., Lee M., Lau C.B.S., Vickers A., et al. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 2008, 26:4860-4866.
14. Zhang P., Yang Q.B., Marciani D.J., Martin M., Clements J.D., Michalek S.M., et al. Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine 2003, 21:4459-4471.
15. Slovin S.F., Ragupathi G., Fernandez C., Jefferson M.P., Diani M., Wilton A.S., et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21. Vaccine 2005, 23:3114-3123.
16. Quenelle D.C., Collins D.J., Marciani D.J., Kern E.R. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gG) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine 2006, 24:1515-1523.
17. Karanam B., Gambhira R., Peng S., Jagu S., Kim D.J., Ketner G.W., et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009, 27:1040-1050.
18. Ragupathi G., Damani P., Srivastava G., Srivastava O., Sucheck S.J., Ichikawa Y., et al. Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccine. Canc Immunol Immunother 2009, 58:1397-1406.
19. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
20. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977, 83:346-356.
21. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26:2350-2360.
22. Sun H.A., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1797.
23. Hong S.J., Wan J.B., Zhang Y., Hu G., Lin H.C., Seto S.W., et al. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytother Res 2009, 23:677-686.
24. Morisaki N., Watanabe S., Tezuka M., Zenibayashi M., Shiina R., Koyama N., et al. Mechanism of angiogenic effects of saponin from ginseng Radix rubra in human umbilical vein endothelial cells. Br J Pharmacol 1995, 115:1188-1193.
25. Aguilar J.C., Rodríguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25:3752-3763.
26. Schijns V.E., Degen W.G. Vaccine immunopotentiators of the future. Clin Pharmacol Ther 2007, 82:750-755.
27. O'Hagan D.T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its developement?. Clin Pharmacol Ther 2007, 82:740-745.
28. Carter N.J., Plosker G.L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008, 22:279-292.
29. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-9.
30. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008, 358:2573-2584.
31. 23 July 2010. http://www.who.int/vaccine_research/diseases/influenza/flu_trials_tables/en/.
32. Keitel W.A., Atmar R.L. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 2009, 333:431-451.
33. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9:1057-1071.
34. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2436.
35. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PlosOne 2009, 4:e4384-e4390.
36. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Int J Infect Dis 2008, 197:667-676.
37. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2424.
38. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28:1740-1745.
39. Higgins D.A., Carlson J.R., Nest G.V. MF59 adjuvant enahnces the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996, 14:478-485.
40. Cataldo D.M., Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997, 15:1710-1726.
41. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PlosOne 2008, 3:e1401.
42. Deans G.D., Stiver H.G., McElhaney J.E. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med 2010, 267:220-227.
43. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997, 159:105-117.
44. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
45. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006, 13:981-990.
46. De Vries J.J., Bungener L., Ter Veer W., Van Alphen L., Van der Ley P., Wilschut J., et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 2009, 27:947-956.